Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3371 | Ringer solution Wiki | 1.00 |
| drug4021 | Tissue plasminogen activator Wiki | 1.00 |
| drug1396 | Enoxaparin Wiki | 0.27 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.09 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Coronavirus Disease (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has led to unprecedented morbidity and mortality in the modern era. To date, nearly 13 million people have contracted COVID-19, leading to more than 550,000 deaths worldwide. As the number of affected individuals continues to climb, effective strategies for treatment and prevention of the disease are of paramount importance. SARS-CoV-2 is understood to directly invade cells via the human angiotensin-converting enzyme 2 (ACE2) receptor, which is expressed predominantly in the lungs but also throughout the cardiovascular system. Thus, while acute respiratory distress syndrome remains a feared complication, new thromboembolic disease has emerged as a common and potentially catastrophic manifestation of COVID-19.
Description: The time to first event rate within 30 days of randomization of the composite of all-cause mortality, intubation requiring mechanical ventilation, systemic thromboembolism (including pulmonary emboli) confirmed by imaging or requiring surgical intervention OR ischemic stroke confirmed by imaging.
Measure: Time to first event Time: 30 daysDescription: Number of in-hospital rate of BARC 3 or 5 bleeding (binary). BARC Type 3: a. Overt bleeding plus hemoglobin drop of 3 to < 5 g/dL (provided hemoglobin drop is related to bleed); transfusion with overt bleeding b. Overt bleeding plus hemoglobin drop < 5 g/dL (provided hemoglobin drop is related to bleed); cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring IV vasoactive agents c. Intracranial hemorrhage confirmed by autopsy, imaging, or lumbar puncture; intraocular bleed compromising vision. BARC Type 5: Probable fatal bleeding Definite fatal bleeding (overt or autopsy or imaging confirmation)
Measure: Number of in-hospital rate of BARC 3 or 5 Time: 30 daysDescription: Myocardial infarction (according to the 4th universal definition, types 1,2, and 3)
Measure: Number of participants with Myocardial infarction Time: 30 days after randomizationDescription: Myocardial infarction (according to the 4th universal definition, types 1,2, and 3)
Measure: Number of participants with Myocardial infarction Time: 90 days after randomizationDescription: Deep vein thrombosis with confirmation on imaging
Measure: Number of participants with Deep Vein Thrombosis Time: 30 days after randomizationDescription: Deep vein thrombosis with confirmation on imaging
Measure: Number of participants with Deep Vein Thrombosis Time: 90 days after randomizationDescription: Intubation and mechanical ventilation
Measure: Number of participants requiring Ventilation Time: 30 after randomizationDescription: Intubation and mechanical ventilation
Measure: Number of participants requiring Ventilation Time: 90 days after randomizationDescription: All-cause death
Measure: Number of All Death Time: 30 days after randomizationDescription: All-cause death
Measure: Number of All Death Time: 90 days after randomizationDescription: Cause of Death
Measure: Cause of Death Time: 30 days after randomizationDescription: Cause of Death
Measure: Cause of Death Time: 90 days after randomizationDescription: Stroke confirmed by imaging or autopsy (all, ischemic and hemorrhagic)
Measure: Number of participants with Stroke Time: 30 days after randomizationDescription: Stroke confirmed by imaging or autopsy (all, ischemic and hemorrhagic)
Measure: Number of participants with Stroke Time: 90 days after randomizationDescription: Pulmonary emboli confirmed by imaging or autopsy
Measure: Number of participants with Pulmonary Emboli Time: 30 days after randomizationDescription: Pulmonary emboli confirmed by imaging or autopsy
Measure: Number of participants with Pulmonary Emboli Time: 90 days after randomizationDescription: Systemic thromboembolism confirmed by imaging or requiring surgical intervention
Measure: Number of participants with Systemic Thromboembolism Time: 30 days after randomizationDescription: Systemic thromboembolism confirmed by imaging or requiring surgical intervention
Measure: Number of participants with Systemic Thromboembolism Time: 90 days after randomizationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports